MolNFT v1 · #2339 · protein
Human serum transferrin, recombinant N-terminal lobe, apo form, crystal form 2
1BTJ · Protein (serum transferrin): “Human serum transferrin, recombinant N-terminal lobe, apo form, crystal form 2”. X-ray diffraction, 4 pockets (best druggability 0.36). MolNFT v1 #2339 on GenesisL1: 3D structure, binding sites and…
- PDB
- 1BTJ
- Type
- protein
- Length
- 666 residues
- Chains
- 2
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Protein (serum transferrin)
- UniProt
- P02787
- Pockets
- 4 · best druggability 0.36
Structure
x-ray diffraction · 1 distinct chain · 35% helix, 21% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A, B | Protein (serum transferrin) | protein | 333 | 35% helix, 21% strand | P02787 |
Pockets
4 pockets found on a 1 Å grid, 0 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 109 | 0.36 | 0.74 | 24 | empty |
| 2 | 106 | 0.36 | 0.74 | 23 | empty |
| 3 | 62 | 0.32 | 0.76 | 15 | empty |
| 4 | 57 | 0.31 | 0.76 | 15 | empty |
Modifications
Observed in the structure: 16 disulfide (disulfide).
Compared structures
- 1BTJ · Human serum transferrin, recombinant N-terminal lobe, apo form, crystal form 2 · the same entry in another collection · chain A against A, TM-score 1.00
- P02787 · AlphaFold monomer V2.0 prediction for serotransferrin (P02787) · a predicted model of the same protein · chain A against A, TM-score 0.65
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt P02787
- Elsewhere: RCSB PDB 1BTJ · PDBe 1BTJ · UniProt P02787
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.